# Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

> **NCT04058964** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Pegylated Recombinant Human Hyaluronidase PH20
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04058964
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-02-01
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn by supporter
- **Last updated:** 2020-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04058964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04058964, "Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04058964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*